{
    "name": "alprostadil intracavernous/urethral",
    "comment": "Rx",
    "other_names": [
        "Caverject",
        "Edex",
        "Muse",
        "PGE1",
        "Prostaglandin E1",
        "Viridal"
    ],
    "classes": [
        "Prostaglandins",
        "Genitourinary"
    ],
    "source": "https://reference.medscape.com/drug/caverject-edex-alprostadil-342846",
    "pregnancy": {
        "common": [
            "Pregnancy: Alprostadil not indicated for use in females",
            "Lactation: Alprostadil not indicated for use in females"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Alprostadil not indicated for use in females"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Predisposition to priapism (eg, sickle cell anemia, sickle cell trait, multiple myeloma, leukemia)",
                "Anatomical deformation of the penis, such as cavernosal fibrosis or Peyronie’s disease",
                "Penile implants",
                "Sexual intercourse with pregnant woman unless condom barrier used (intracavernosal implant)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Discontinue therapy if signs of penile fibrosis develop",
                "The preservative benzyl alcohol contained in the intracavernosal dosage form has been associated with serious adverse events, including the “gasping syndrome”, and death in pediatric patients; this dosage form is not indicated for pediatric patients",
                "Syncope reported within 1 hr of using urethral suppository (pellet)",
                "The risk of breakage with superfine needles is high; needle breakage, with a portion of the needle remaining in the penis, requiring hospitalization and surgical removal reported; careful instruction in proper patient handling and injection techniques may minimize potential for breakage",
                "Patients with bleeding disorders or on anticoagulants, such as warfarin or heparin may have increased propensity for bleeding after intracavernosal injection; use caution; compress site of injection with alcohol swab or sterile gauze for 5 min",
                "Diagnose and treat underlying treatable medical causes of erectile dysfunction before initiating therapy",
                "Safety and efficacy of combinations of drug and other vasoactive agents injected intracavernosally not established in clinical studies; risks of prolonged erection, priapism, and hypotension may be increased",
                "Injections can lead to increased peripheral blood levels of alprostadil, especially in patients with significant corpora cavernosa venous leakage; avoid use in patients with known cavernosal venous leakage; may cause hypotension",
                "Counsel patients about protective measures necessary to guard against sexually transmitted disease including human immunodeficiency virus (HIV)"
            ],
            "specific": [
                {
                    "type": "Cardiovascular risk",
                    "description": [
                        "Physical examination of penis should be performed periodically, to detect signs of penile fibrosis; treatment should be discontinued in patients who develop penile angulation or cavernosal fibrosis",
                        "There is a potential for cardiac risk of sexual activity in patients with preexisting cardiovascular disease; treatments for erectile dysfunction should not be used in men for whom sexual activity is inadvisable because of their underlying cardiovascular status",
                        "The evaluation of erectile dysfunction should include a determination of potential underlying causes and the identification of appropriate treatment following a complete medical assessment"
                    ]
                },
                {
                    "type": "Priapism",
                    "description": [
                        "Prolonged erection defined as erection lasting between 4 to 6 hours in duration reported; in the event of an erection that persists longer than 4 hours, the patient should seek immediate medical assistance; if priapism not treated immediately, penile tissue damage and permanent loss of potency may result To minimize chances of prolonged erection or priapism, drug should be titrated slowly to lowest effective dose",
                        "Not for use in patients who have conditions that predispose them to priapism, such as sickle cell anemia or sickle cell trait, multiple myeloma, or leukemia"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eluxadoline",
            "description": {
                "common": "eluxadoline increases levels of alprostadil intracavernous/urethral by decreasing metabolism. Use Caution/Monitor. Eluxadoline may increase the systemic exposure of coadministered OATP1B1 substrates."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "antithrombin alfa",
            "description": {
                "common": "alprostadil intracavernous/urethral increases effects of antithrombin alfa by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "antithrombin III",
            "description": {
                "common": "alprostadil intracavernous/urethral increases effects of antithrombin III by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "argatroban",
            "description": {
                "common": "alprostadil intracavernous/urethral increases effects of argatroban by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bemiparin",
            "description": {
                "common": "alprostadil intracavernous/urethral increases effects of bemiparin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bivalirudin",
            "description": {
                "common": "alprostadil intracavernous/urethral increases effects of bivalirudin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dalteparin",
            "description": {
                "common": "alprostadil intracavernous/urethral increases effects of dalteparin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "enoxaparin",
            "description": {
                "common": "alprostadil intracavernous/urethral increases effects of enoxaparin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fondaparinux",
            "description": {
                "common": "alprostadil intracavernous/urethral increases effects of fondaparinux by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "heparin",
            "description": {
                "common": "alprostadil intracavernous/urethral increases effects of heparin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phenindione",
            "description": {
                "common": "alprostadil intracavernous/urethral increases effects of phenindione by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "protamine",
            "description": {
                "common": "alprostadil intracavernous/urethral increases effects of protamine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Penile pain",
            "percent": "32"
        },
        {
            "name": "Urethral burning",
            "percent": "12"
        },
        {
            "name": "Penile pain",
            "percent": "37"
        },
        {
            "name": "Urethral bleeding",
            "percent": "5"
        },
        {
            "name": "spotting",
            "percent": "5"
        },
        {
            "name": "Testicular pain",
            "percent": "3"
        },
        {
            "name": "Headache",
            "percent": "4-6"
        },
        {
            "name": "Prolonged erection",
            "percent": "4"
        },
        {
            "name": "hr",
            "percent": "3"
        },
        {
            "name": "Penile fibrosis",
            "percent": "3"
        },
        {
            "name": "Injection site hematoma",
            "percent": "2"
        },
        {
            "name": "Injection site echymosis",
            "percent": "1"
        },
        {
            "name": "Penile rash",
            "percent": "1"
        },
        {
            "name": "Penile edema",
            "percent": "0.4"
        },
        {
            "name": "Syncope",
            "percent": "6"
        },
        {
            "name": "Tachycardia",
            "percent": "0.4"
        },
        {
            "name": "leg pain",
            "percent": null
        },
        {
            "name": "perineal pain",
            "percent": null
        },
        {
            "name": "Priapism",
            "percent": null
        },
        {
            "name": "hr",
            "percent": null
        },
        {
            "name": "Injection site hemorrhage",
            "percent": null
        }
    ]
}